H F Tse1, Q Wang, C M Yu, G M Ayers, C P Lau. 1. Division of Cardiology, Department of Medicine, University of Hong Kong, Queen Mary Hospital, Hong Kong, China.
Abstract
BACKGROUND: The role of verapamil in the prevention of atrial fibrillation (AF) in patients with recurrent AF is unknown. HYPOTHESIS: The aim of this study was to evaluate the effect of verapamil on the prevention of AF in patients implanted with an implantable atrial defibrillator (IAD). METHODS: The effects of verapamil (240 mg/day) on the total duration of AF, number of AF recurrences, and number of cardioversions were prospectively evaluated in a randomized, crossover fashion over an 8-week period in 11 patients (9 men, 2 women; mean age: 60 +/- 6 years) implanted with an IAD. RESULTS: Implantable atrial defibrillators successfully converted 13 of 14 (93%) spontaneous episodes of AF. There was no significant difference in the efficacy of cardioversion (86 vs. 100%, p = 0.8), the total duration of AF (173 +/- 198 vs. 270 +/- 241 h, p = 0.5), the number of AF episodes (8.5 +/- 9.0 vs. 9.3 +/- 10.2, p = 0.3), and the number of cardioversions (1.7 +/- 2.4 vs. 1.8 +/- 2.1 p = 0.7) with or without treatment with verapamil. CONCLUSIONS: The results of the present study suggest that treatment with verapamil has no significant effect on the prevention of AF in patients treated with an LAD.
RCT Entities:
BACKGROUND: The role of verapamil in the prevention of atrial fibrillation (AF) in patients with recurrent AF is unknown. HYPOTHESIS: The aim of this study was to evaluate the effect of verapamil on the prevention of AF in patients implanted with an implantable atrial defibrillator (IAD). METHODS: The effects of verapamil (240 mg/day) on the total duration of AF, number of AF recurrences, and number of cardioversions were prospectively evaluated in a randomized, crossover fashion over an 8-week period in 11 patients (9 men, 2 women; mean age: 60 +/- 6 years) implanted with an IAD. RESULTS: Implantable atrial defibrillators successfully converted 13 of 14 (93%) spontaneous episodes of AF. There was no significant difference in the efficacy of cardioversion (86 vs. 100%, p = 0.8), the total duration of AF (173 +/- 198 vs. 270 +/- 241 h, p = 0.5), the number of AF episodes (8.5 +/- 9.0 vs. 9.3 +/- 10.2, p = 0.3), and the number of cardioversions (1.7 +/- 2.4 vs. 1.8 +/- 2.1 p = 0.7) with or without treatment with verapamil. CONCLUSIONS: The results of the present study suggest that treatment with verapamil has no significant effect on the prevention of AF in patients treated with an LAD.
Authors: I C Van Gelder; B J Brundel; R H Henning; A E Tuinenburg; R G Tieleman; L Deelman; J G Grandjean; P J De Kam; W H Van Gilst; H J Crijns Journal: J Cardiovasc Electrophysiol Date: 1999-04
Authors: E G Daoud; P Marcovitz; B P Knight; R Goyal; K C Man; S A Strickberger; W F Armstrong; F Morady Journal: Circulation Date: 1999-06-15 Impact factor: 29.690
Authors: A De Simone; G Stabile; D F Vitale; P Turco; M Di Stasio; F Petrazzuoli; M Gasparini; C De Matteis; R Rotunno; T Di Napoli Journal: J Am Coll Cardiol Date: 1999-09 Impact factor: 24.094
Authors: C-J A Lindholm; O Fredholm; S-J Möller; N Edvardsson; T Kronvall; T Pettersson; V Firsovaite; A Roijer; C J Meurling; P G Platonov; S B Olsson Journal: Heart Date: 2004-05 Impact factor: 5.994